CD274 and neoplasm: Although certain tumor tissue-based biomarkers such as PD-L1 expression as well as tumor mutational burden (TMB) are associated with an increased likelihood to respond to the immune-checkpoint blockade, PD-L1 scoring systems and defined TMB cutoff values are not uniformly applicable across tumor entities, and PD-L1 negativity or a low TMB do not exclude responses.